bioMérieux receives Emergency Use Authorization for BIOFIRE® COVID-19 test

24 March, 2020

bioMérieux, a world leader in the field of in vitro diagnostics, today announced that its subsidiary, BioFire Defense, has received Emergency Use Authorization by the U.S. Food and Drug Administration of its BIOFIRE® COVID-19 test for use in CLIA moderate and high complexity clinical...

E.g., 11/27/2021
E.g., 11/27/2021

ExonHit and bioMérieux reach an important research milestone in the molecular detection of breast cancer from blood samples

29 March, 2006

ExonHit Therapeutics, a French drug and diagnostic discovery company, and bioMérieux, a major player in the field of in vitro diagnostics, announce today that they have reached an important research milestone in the diagnosis of breast cancer.

bioMérieux launches an avian flu test for research purposes

02 February, 2006

As a major player in the field of in vitro diagnostics, bioMérieux confirms its commitment to the fight against emerging diseases and launches its avian flu detection test.

bioMérieux Editions publishes a book on hospital-acquired infections

09 November, 2005

bioMérieux annonce la parution d’un ouvrage consacré aux Infections Liées aux Soins (ILS). Ce livre a été élaboré par les professeurs Marie-Laure Joly-Guillou et Bernard Régnier. Le Docteur Jean Carlet en a signé la préface.

bioMérieux and ExonHit Therapeutics Extend their Strategic Collaboration

13 October, 2005

bioMérieux and ExonHit announced today that they signed an agreement to extend their collaboration for six years for the discovery and development of new blood diagnostics in the area of early cancer detection.

DiagnoSwiss and bioMérieux announce that they have signed an exclusive license agreement for the development and use of DiagnoSwiss electrochemical microchips in human in vitro diagnostics

27 July, 2005

Monthey (Switzerland) – bioMérieux and DiagnoSwiss announced today that DiagnoSwiss has granted bioMérieux with an exclusive worldwide license under the patent rights of DiagnoSwiss relating to the development, manufacturing and marketing of electrochemical microchips in the field of human in vitro diagnostics.

Hepanostika® HBsAg Ultra – New “ultra”-sensitive test for Hepatitis B infection from bioMérieux

05 July, 2005

bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of its new microelisa assay for the detection of hepatitis B surface antigen. Hepanostika® HBsAg Ultra is officially presented at the XV European Regional Congress of the International Society of Blood Transfusion (ISBT) currently being held from July 2-6 in Athens, Greece.

Hospices Civils de Lyon and bioMérieux inaugurate a joint immunogenomics and inflammation unit

23 June, 2005

Hospices Civils de Lyon (HCL) and bioMérieux will inaugurate today the “HCL-bioMérieux” joint unit dedicated to research in immunogenomics and inflammation. The unit is headed by Prof. Pierre Miossec and Bruno Mougin.

MRSA ID - bioMérieux’s latest contribution to the fight against nosocomial infections

25 May, 2005

A world leader in the field of in vitro diagnostics, bioMérieux SA announces the launch of a new product for rapid, reliable identification of Methicillin-Resistant Staphylococcus aureus, a common cause of nosocomial infections.

Pioneering Diagnostics